Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Skinvisible (SKVI) Liabilities and Shareholders Equity (2016 - 2025)

Skinvisible's Liabilities and Shareholders Equity history spans 16 years, with the latest figure at $133623.0 for Q3 2025.

  • For Q3 2025, Liabilities and Shareholders Equity fell 10.1% year-over-year to $133623.0; the TTM value through Sep 2025 reached $584769.0, down 6.88%, while the annual FY2024 figure was $158217.0, 2.86% down from the prior year.
  • Liabilities and Shareholders Equity for Q3 2025 was $133623.0 at Skinvisible, down from $143375.0 in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $320590.0 in Q2 2022 and bottomed at $133623.0 in Q3 2025.
  • The 5-year median for Liabilities and Shareholders Equity is $183588.0 (2022), against an average of $193301.2.
  • The largest annual shift saw Liabilities and Shareholders Equity soared 38.91% in 2022 before it tumbled 38.76% in 2023.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $227299.0 in 2021, then grew by 8.58% to $246793.0 in 2022, then plummeted by 34.01% to $162869.0 in 2023, then dropped by 2.86% to $158217.0 in 2024, then decreased by 15.54% to $133623.0 in 2025.
  • Per Business Quant, the three most recent readings for SKVI's Liabilities and Shareholders Equity are $133623.0 (Q3 2025), $143375.0 (Q2 2025), and $149554.0 (Q1 2025).